Industry Trend Analysis in the Pharma Secondary Packaging Market
An overview of the global pharmaceutical logistics market
Keeping pharmaceutical products undamaged and therapeutically effective during their journey to the market can often prove to be an arduous and complex task. Once outside the sterile manufacturing and packaging facility, the risk of product contamination during the pharmaceutical logistics process can be high. The handling of temperature-controlled pharmaceutical products during the pharma logistics process is a complicated business irrespective of the mode of transport and presents unique challenges. Furthermore, the pharmaceutical industry is heavily segmented, resulting in an increased level of M& activity in the sector. The pharmaceutical industry is also experiencing a geographic shift in its major production locations and sales markets. Asia and South America, in particular, are becoming increasingly attractive markets for companies in the sector. But these markets are regarded as the most challenging in terms of supply chain and pharmaceutical logistics operations. As technology and innovation in the pharmaceutical space mature, we can expect advanced and risk-free pharma supply chain and logistics processes in the near future. In this article, Infiniti’s thought leaders answer some key questions relating to pharmaceutical logistics.
What are some of the biggest pharmaceutical logistics challenges facing companies currently?
Supply chain visibility is one of the key challenges facing pharmaceutical logistics. This could become a serious challenge especially for companies that intensively deal with regulatory affairs. Pharma manufacturers must overcome this barrier as better supply chain visibility into pharmaceutical logistics as it helps enhance shipment lead times, analyze customer sales projections can drive efficiency benefits, reduce inventories, and improve fulfillment rates. Furthermore, challenges related to increased globalization are presenting suppliers, consumers, and regulatory bodies in the pharmaceutical logistics space with increased risk and uncertainties.
What are some of the key region-specific insights on pharmaceutical logistics?
Pharma logistics are highly mature in Western Europe and the United States. In the future, we can expect least number of supply chain issues from Nordic countries. At present, emerging markets including China and Southeast Asia, the Middle East, South America, and Eastern Europe look highly lucrative for growth in the pharmaceutical industry. As the demand for modern medical treatments and healthcare products rises in these emerging and ‘high-potential’ nations, pharmaceutical companies are moving to unfamiliar territories and cultures and also learning about the accompanying supply chain challenges in these regions. These roadblocks include unstable regulatory environment and underdeveloped logistics infrastructure.
Why is it beneficial for pharma companies to outsource logistics services?
Most of the top benefits of outsourcing pharmaceutical logistics and supply chain include cost benefits. Outsourcing transportation and warehousing help life sciences companies to considerably reduce their overall costs. However, outsourcing does not completely solve supply chain visibility challenges. Moreover, factors including the rise of generics, the fall of the blockbuster model, and a sharp increase in R&D cost are putting companies in the pharmaceutical industry under pressure to bring down costs. Outsourcing logistics is an effective way to reduce the overall costs and also reduce the total time-to-market.
What criteria are most important while choosing a logistics service provider?
Consistency and reliability of services are two key traits that are paramount characteristics to consider while selecting a pharmaceutical logistics service provider. The provider’s industry experience and reputation in terms of safety and security of material handling should also be taken into consideration. Top pharmaceutical companies are already using outsourcing as a strategic part of the company’s overall business strategy especially to establish consistency and efficiency across the international supply chain network. To ensure continued partnership with pharmaceutical companies, logistics service providers must safeguard the confidentiality of the proprietary knowledge, prove its reliability in services, offer continuous improvements, and comply with the regulatory requirements of their clients.
Regenerative medicine is currently the hive of innovation in modern science with far-reaching benefits for big pharma, healthcare systems, and patient outcomes. We can expect a rapid pace of development in the US regenerative medicine market over the next decade. Some of the key factors fueling demand include the increasing investments in R&D activities and the rising incidence of chronic diseases in the country. Leading vendors have enhanced their R&D investments to develop innovative medical therapies, which is driving the overall growth of the market. Furthermore, M&A and strategic alliances among vendors will have a significant impact on the overall market growth and innovation. Nevertheless, the actual delivery of regenerative medicines has proven to be rather challenging with several roadblocks to commercially viable therapies that are capable of catering to unmet clinical needs. In this article, based on a series of discussions with industry analysts at Infiniti Research, we highlight some of the most relevant and pressing manufacturing challenges in regenerative medicine products.
Regenerative medicine manufacturing challenges
Cell therapy manufacturing processes are generally highly expensive. Scaling up from limited laboratory facilities to automated systems for bulk production will largely be based on cost, therefore impeccable financial and time planning become vital. As a first-generation technology, stakeholders we can expect greater stakeholder tolerance for higher pricing, but this will only be for a limited time period.
After collecting sufficient evidence of clinical effectiveness of regenerative medicines, bioreactor technologies are considered for the manufacture of regenerative medicine products. But even minor process changes at this stage will require new validation of the product performance. So, in the case of automation, robots manually reproduce the existing inefficient manual processes due to which the products are often based on obsolete technologies. As a result, the manufacture of regenerative medicines sometimes misses the opportunity to improve their quality by innovating process design.
Challenges relating to biomaterials is mostly concerned with their selection than the manufacturing. The trends in material selection will eventually have a major impact on the manufacturing process. As traditional synthetic biodegradable polymers and a few bioactive ceramics that have been manufactured through conventional routes are no longer considered ideal, attention is now being turned toward biomaterials that have more relevant biological properties. But since they have critical nanostructural features, and may involve self-assembly and environmental responsiveness, they may not be compatible with normal top-down manufacturing and therefore could require changes in the production process.
Supply chain challenges
The clinical supply chains required to deliver regenerative medicines therapies are arguably the most complex the industry has seen so far, even more so than for biologic medicine. At present, while billions of dollars are being spent on regenerative medicine research and clinical studies, resources are yet to be allocated to the management and delivery of innovative medical therapies at scale. Furthermore, progress by the pharma industry in coming into compliance with the FDA’s regulations for regenerative medicines has been slow. This makes the process of bringing regenerative medicines at scale to the market even more challenging.
Pharmaceutical Industry Analysis
The innovations in advanced biologics, rising population, and access to quality healthcare and pharmaceuticals to middle-class people worldwide are driving the growth of the global pharmaceutical industry. However, the fluctuating economy, legal issues, talent shortage, massive flow of generic medicines, and rising competition are expected to impact the growth prospect of the global pharmaceutical industry. Besides, companies in the pharmaceutical industry are facing decreasing return on investment due to price erosion in key markets. As such, companies in the pharmaceutical industry will need to foresee changing market dynamics and look for other markets to sustain growth.
The client is a pharma company based out of the United States.
As Canada is known to be one of the most profitable markets for pharmaceutical companies, the client wanted to expand their business operations to Canada. Before investing a huge sum into their expansion plan, they wanted to determine their growth potential and assess market opportunities in the Canadian pharmaceutical industry. They approached the experts at Infiniti Research to leverage their expertise in offering market intelligence engagement.
Other challenges that the client encountered were:
Government and security: As policies regarding the use of medicines varied in different countries, the client wanted to understand the policies in the Canadian pharmaceutical industry. In addition, they wanted to understand in-detail the procedure for new drug launch in Canada.
Massive flow of generic medicines: Due to the massive flow of less expensive or generic drugs in Canada, the client wanted to identify strategies to cut down on their production costs and gain a competitive edge.
Identifying the right set of customers: Before expanding their operations to Canada, they wanted to identify the profitable customers to focus on to drive sales.
Need for new and effective medicines: The client wanted to analyze competitors’ product offerings and identify drugs gaining popularity in the Canadian pharmaceutical industry. By doing so, they wanted to invest into similar drugs.
The experts at Infiniti Research followed a four-phased approach that involved:
Market scanning and monitoring analysis to understand the regulatory changes in the Canadian pharmaceutical industry. This also involved evaluating the market potential for the client’s offerings in Canada and identifying the capital requirement for setting up new production and distribution units.
Technology assessment to spot the next technological breakthrough and identify cost-effective technologies to enhance the client’s operational efficiency.
Customer segmentation analysis to segregate customers into distinct target segments and identify profitable customer groups.
Competitive intelligence solution to analyze the product and service offerings of the top pharma companies in Canada.
By understanding the current market dynamics and forecasting the potential business opportunities in the Canadian pharmaceutical industry, the client was able to devise a sound market entry plan. Also, by thoroughly understanding the procedures for launching a new product in Canada, they were able to succeed clinical trials in their initial attempt. In addition, the adoption of cost-effective technologies helped the client to automate their operations and reduce production costs. This further helped them to reduce the costs of their drugs and better compete with generic drug manufacturers.
By identifying the right set of customers, the company in the pharma industry was able to personalize their marketing and sales efforts for them and generate maximum sales. Also, a detailed analysis of their competitors’ offerings helped them to competitively price their products. Within two years of entering the Canadian pharmaceutical industry, the client was able to generate huge sales and realize profits of over 29%.
Analyzing Trends in Pharmaceutical Industry
Rising healthcare costs and economic uncertainties have put US pharmaceutical companies in a state of turmoil. However, on the brighter side, with biosimilars gaining popularity and new drug pricing and reimbursement approaches, pharmaceutical companies will witness rapid transformations over the coming year. Hence, pharma companies are under the pressure to stay abreast with the latest market innovations and trends in pharmaceutical industry. This is where companies realize the need to leverage market trend analysis solution.
The client is a Canadian pharmaceutical company. The client was looking to expand their operations to the United States. With rapid transformations happening in the US pharma market, the client wanted to identify the trends in pharmaceutical industry and keep pace with the market innovations. The client, therefore, partnered with Infiniti Research to leverage their expertise in offering market trend analysis solution.
Furthermore, the client wanted to:
Analyze the market potential
By analyzing the trends in pharmaceutical industry and understanding the market innovations, the client wanted to understand the market potential for their product and services in the United States.
Understand technological trends in pharmaceutical industry
With the industry-wide proliferation of cloud technologies and artificial applications (AI) driving pharmaceutical industry growth, the client wanted to analyze all the technological trends in pharmaceutical industry in the United States.
Understand rising demand for biosimilars
With biosimilars gaining popularity in the US pharmaceutical market and providing cost savings for payers and patients, the client wanted to analyze how biosimilars are changing the US pharma market.
Analyze rising drug pricing
With the US government tightening up conditions for drug pricing and related instruments such as rebates and discounts, the client wanted to analyze the trends in pharmaceutical industry related to drug pricing.
As a part of the trend analysis engagement, the experts at Infiniti Research conducted a thorough US pharmaceutical industry analysis and market sizing analysis. This phase of the trend analysis engagement helped the client to understand the recent market developments and estimate the market potential for their products and services. Also, the client was able to identify the market size of pharmaceutical industry in the US.
The experts also leveraged product research engagement to help the client analyze the complete product development lifecycle, trade-offs, and gain insights on product-specific revenues to boost the value proposition. Furthermore, the experts analyzed technological trends in pharmaceutical industry and monitored how the client’s major competitors employed the latest technological trends in their business processes.
Furthermore, by leveraging Infiniti’s expertise in conducting industry trend analysis engagement, the experts helped the client to understand how biosimilars are transforming the US pharma industry and analyzed how top US pharma companies are spending on biosimilars.
By leveraging Infiniti’s expertise in offering market opportunity analysis, the experts also helped the client to review potential barriers to market entry and assess markets’ readiness for their product and service offerings.
With Infiniti’s market trend analysis engagement, the client was able to efficiently analyze the trends in pharmaceutical industry and stay abreast with market innovations. Also, tracking emerging trends in pharmaceutical industry and assessing the regional market developments helped the client to devise a market entry plan to enter the US pharma market. Furthermore, within two years of entering the new market, the client was able to achieve a leading edge in the US pharma market and become one among the top 20 pharma companies in the United States.
Trends in Pharmaceutical Industry
The pharma industry is undergoing a myriad of changes. Therefore, success in today’s pharmaceutical marketplace largely depends on companies’ ability to continually reassess strategic direction, move with agility, and anticipate and adapt to changes. Businesses must not only keep a close watch on the pharma industry trends, but equal emphasis should be given to tackling the upcoming challenges. Some of the key challenges identified during our pharma industry analysis include:
- Increasing instances of chronic diseases are placing greater pressure on the healthcare budgets
- Healthcare policy makers are increasing pressure on doctors regarding what to prescribe
- Growing demand for medicines in emerging economies
- Regulators are becoming increasingly cautious while approving new and innovative medicines
- Pharma-economic performance is measured in order to insist on outcome-based pricing
Pharma industry trends
Despite these challenges, there are several exciting pharma industry trends underway. Infiniti Research’s pharma industry analysis reveals the following trends that companies in this sector must gear up for:
Prevention over treatment
One of the key pharma industry trends that are expected to go mainstream is the idea of prevention over treatment. Governments across the globe are backing this, especially in the case of chronic diseases. Global pharmaceutical industry analysis suggests that there is an unprecedented amount of supply in prevention supplements and pills around the world. If certain chronic diseases cannot be treated, some of its symptoms and fatal consequences can be prevented through such initiatives.
Reverse innovation refers to any innovation which is adopted first by emerging economies and then distributed globally. Pharma industry trends of the future such as reverse innovation provide answers to various challenges faced by companies in the pharma industry including the rising research costs, patent expiration, and consequent revenue declines, and huge costs in bringing a drug to market.
Nanotechnology is one of the most notable recent trends in the pharmaceutical industry. Nanotechnology is a scientific, multi-disciplinary effort that involves the creation and utilization of essence systems on a nanometer scale. An important application of this innovation is in the form of ‘Nano-medicine’. Pharma industry experts at Infiniti Research believe nanotechnology to be one of the most impressive pharma industry trends and will unleash several breakthroughs in medicine, diagnosis, and genetic engineering. A key example of an innovative nanomedicine is that of Genexol-PM which is an anti-cancer drug used to fight breast cancer and non-small lung cancer.
Customization or personalized medicine
People around the globe are known to have genetic differences, however, all of us consume similar medicine that has been designed for millions of people. However, this trend is about to change in the near future. Personalized medicine is expected to become one of the most favored pharma industry trends in the future. The drugs will be customized based on the patient’s examination reports and medical records. Though it would take some time for this to become full-fledged in the pharma industry, such trends in the pharma industry will provide enhanced treatment to the patients.
3D printers are under rapid development. The adaptation of this technology in the pharma industry will enable companies in the sector to print the necessary medicines as per requirements. In 2015, the first FDA approved a drug called Spritam was printed. This drug is used to treat epilepsy. This pill was made 3D printing several layers of the powdered drug, binding the layers of powder together, and blowing away the excess powder. The drug easily dissolves when compared to a traditional pill due to its unique structure. This is especially useful for cases where otherwise large, hard-to-swallow pills are prescribed.
Body sensors are breakthrough pharma industry trends that are all set to revamp patient-care and drug prescription. Wearables, integrated body chip, mini robots, and several other types of body sensors can obtain patient information and communicate the same immediately to the healthcare professionals. This can help them make quick and informed decisions regarding the drugs that need to be prescribed to the patient. These systems integrate living human cells with micro-engineering to help researchers and product development teams a new standard for predicting human response with greater precision.
Artificial intelligence and cognitive computers help gather and classify large volumes of data in a matter of seconds. This solves the common problem that the drug discovery process is lengthy and expensive. These advanced technologies will also help pharma companies to run cognitive trials in lesser time. Which means drugs can be delivered to patients much earlier than before.
GET MORE INFO to know more about Infiniti’s solutions for business
The global economic uncertainties, increasing healthcare costs and expiring patents are putting pharma companies in a state of turmoil. However, on the brighter side, the rapid development of the emerging markets, progress in drug research, the rise in generics production, the availability of high-potency drugs, and innovations in manufacturing trends will sustainably modify the global pharmaceutical landscape. Moreover, the increasing prevalence of chronic diseases and the growing demand for medications, high market growth, new medicines, and therapy forms, changing regulations, and progressing digitization are going to give birth to new manufacturing trends to meet the growing demand.
Manufacturing trends in the pharma industry
Process analytical technology
This initiative sets a legal framework in the USA aiming to motivate pharma companies to improve the production process and achieve consistent quality while reducing waste and costs. In order to comply with this regulation and the changing manufacturing trends, pharma companies need to have systems in place that ensure detailed monitoring of their continuous and batch processes. Process analytical technology is one of the vital manufacturing trends that enables and drives continuous manufacturing. It was identified as one of the most important manufacturing trends in pharma companies along with integrated manufacturing business and automation processes.
Digitization and labeling information
Effective tracking, tracing, and labeling is a mandatory proof of authenticity and prevention of drug counterfeiting. Digitization of labeling information has resulted in greater emphasis being placed on collecting, securing, and processing digital data about pharma products.
There are several issues relating to introducing new drugs in the market. This includes manufacturing issues as well, so a review of manufacturing trends in approvals of new molecular entities (NMEs) can provide insight into manufacturing activity. A key trend in NME approvals is the increased share of orphan drugs approved as NMEs. Orphan drugs are defined as drugs that treat diseases which are known to affect 200,000 or fewer people, as defined by the US Food and Drug Administration (FDA). The FDA provides incentives, including market-exclusivity benefits, for developing orphan drugs. Due to a smaller patient population, these drugs are typically produced in lower volumes when compared to primary care drugs.
Risk-based manufacturing inspections
The FDA is continuing its plan to use a risk-based selection model for manufacturing inspections in the pharma industry. This forms a part of its strategy to allocate resources more effectively and gain greater parity between inspections of domestic and foreign drug-manufacturing facilities. During September 2018), the FDA published an internal policy that outlines the agency’s risk-based, site-selection model for inspecting foreign drug-manufacturing facilities. The FDA prioritizes inspections of sites regardless of their location with the help of a risk-based site-selection model. This is one of the critical manufacturing trends that pharma companies must watch out for.
Gain more insights into how Infiniti’s solutions can help pharma companies
The rising costs and growing complexities associated with developing and bringing products to the market are compelling life sciences industry players to reexamine their business operations. Click To Tweet
Breakthrough developments in drug manufacturing processes have resulted in groundbreaking results that are set to bring in a major transformation in the life sciences industry. However, players will have to tackle major challenges to innovate and evolve in a complex market. Factors such as the need to improve time-to-market and siloed legacy systems are persistent challenges for players in the life sciences industry. Also, the life sciences industry players must possess the ability to quickly gauge the market to meet operational, infrastructure requirements, and devise appropriate market entry startegies.
The Business Challenge
- The Client: A life sciences industry major
One of the leading life sciences industry player operating in India wanted to devise an effective strategy to enter the international market. Their decision to enter the overseas market opened distinct new opportunities; thereby, making it difficult for the client to prioritize and gauge the risks in every new market. Hence to develop a precise strategy the client approached Infiniti Research to leverage its expertise in market entry strategy development.
Market Entry Strategy Benefits
The foremost step in launching a product or service deals with the selection of a potential market segment. Though this seems obvious, organizations generally fail to do their due diligence as far as pre-market entry strategies are considered. Moreover, research on the market size, growth prospects, competitive landscape, and technological adoption, it is essential not to disregard other essential factors that affect market growth including- economic landscape, business environment, and consumer groups. Seemingly similar economies can present stark differences in such indicators leading to sharply divergent market prospects.
Hence, a systematic and comprehensive approach to analyzing the factors that affect market potential is a good starting point for any organization and that is what Infiniti’s Market Entry Strategy Solutions are all about. Though the market entry strategy is developed with regards to developing market segments it is equally valid for developed economies.
Summary of Our Market Entry Strategy Engagement
To help the life sciences industry player venture into international markets– the experts at Infiniti conducted a detailed market survey to help them gain a better understanding of the potential factors affecting growth in the life sciences industry.
Solution Benefits and the Business Impact
The market entry strategy solution enabled the client to identify the potential beachhead segment to focus and leverage market entry efforts. It also enabled them to select the appropriate business model to maximize profitability.
The are several reasons why businesses focus on expanding their reach by entering international markets. As far as the life sciences market is considered; lower costs, greater profits, and technological advancements are factors that compel them to enter new market segments. However, prior to undertaking a market entry strategy, it is essential to gain a comprehensive insight into the organizations’ readiness to enter the new segment.
Moreover, the life sciences industry is on the verge of a major industrial transformation which is why leading players are looking at devising an effective market entry strategy to expand their reach. This requires answers to key questions such as- What are the business goals? What measures have been devised to cope with the repercussions of market entry?
A must-read case study for life sciences industry players looking to develop an understanding of the importance of a market entry strategy
The pharma industry faces several challenges ranging from financial issues to others arising due to ethical issues.
The active pharmaceutical ingredient is a part of the drug formulation that produces the desired effect. It has been estimated that around 3,000 active pharmaceutical ingredient manufacturing units operate across the globe. Active pharmaceutical ingredient manufacturers face several challenges that arise due to mergers, acquisitions, and regulatory issues. However, a major challenge that needs to be tackled is the development of low-cost pharmaceutical formulations.
While the active pharmaceutical ingredient manufacturing companies have been primarily focusing on devising low-cost sourcing strategies, the absence of supply assurance has resulted in a decelerating market share. Hence, companies will have to devise appropriate strategies to ensure uninterrupted supply and regain market share. On the other side, several leading active pharmaceutical ingredient manufacturing firms are increasingly investing in building their own R&D facility to pursue new therapeutic areas of interest. Moreover, as the active pharmaceutical ingredient market continues to grow, it’s future will contain more investment and mergers and acquisition opportunities to compete and stay relevant in the changing market landscape.
The Business Challenge
- The client: An active pharmaceutical ingredient manufacturing company
To identify the potential bottlenecks and compliance barriers and successfully launch the new product, the client – a leading active pharmaceutical ingredient manufacturing company – approached Infiniti to develop a product marketing strategy. The client wanted to identify and gauge the attractiveness of the target markets. Also, with the help of focus groups, the active pharmaceutical ingredient manufacturer wanted to make important decisions, which included- pricing, profit goals, distribution, and methods of promotion. Therefore, their primary objective was to develop an executable product marketing strategy aimed at leveraging product sales and profit margins.
How Can a Precise Product Marketing Strategy Help the Pharma Industry?
Whether you deal with product manufacturing or sales, a well-defined product marketing strategy can help you target the right customer segment. Our market experts help you develop a concept and then move into the different stages involved – pricing, market testing, and execution promotion. Also, our product marketing strategy is designed to encompass every aspect of the pharma industry starting from design and development to distribution and sales.
Summary of our product marketing strategy assessment
The solutions offered by Infiniti’s market experts helped the pharma industry client to gain a detailed industry outlook. It also helped the client to identify the target markets and develop a product marketing strategy to reach out to the potential customer segments.
Furthermore, to help the client identify the right distribution channels, the market experts at Infiniti conducted a detailed market assessment to devise executable promotions and marketing campaigns that reach the target market segments. The approach included primary and secondary research methodologies coupled with qualitative and quantitative data collection procedures. The experts also reached out to various stakeholders in the pharma industry.
Solution Benefits and the Business Impact
Infiniti’s product marketing experts helped the pharma industry client to accomplish their organizational objectives through the development of a precise product marketing strategy that helped them leverage sales and boost market share. The marketing strategy also helped the active pharmaceutical ingredient manufacturer to enhance their product offerings.
With the rapid growth of the pharma industry, it might be difficult for active pharmaceutical ingredient manufacturing companies to gauge the attractiveness of their product offerings in different market segments. The growing competitive pressure is also forcing pharma industry players to devise precise product marketing strategies to ensure they reach the potential target segments.
However, to benefit from the ongoing digital revolution, active pharmaceutical ingredient manufacturers will have to embrace disruptive technologies such as – AI-guided therapies, 3D printed drugs, and preventive medicine while collaborating with regulatory firms to ensure the safety of end-users.
A must-read case study for strategy specialists and decision makers looking to develop an understanding of the pharma industry.
In recent times, nutraceuticals have received considerable interest because of their presumed safety and potential nutritional and therapeutic effects. Today, an increasing number of dietary supplements have become available in supermarkets and health food shops, and they are also available for purchase in pharmacies. So, what are nutraceuticals? In a nutshell, they are medicinally or nutritionally functional food products. Nutraceuticals are parts of food that provide medical or health benefits, including the prevention and treatment of disease. They are also addressed by a variety of other synonyms such as medical foods, designer foods, phytochemicals, functional foods, and nutritional supplements. They include everyday products as “bio” yogurts and fortified breakfast cereals, as well as vitamins, herbal remedies, and even genetically modified foods and supplements. The increasing demand for functional food products can be explained by the growing cost of healthcare, the steady increase in life expectancy, and the desire of older people for the improved quality of their later years.
Some of the vital health benefits of nutraceuticals
Brain health and aging
The WHO predicts that by 2020 over 65 million people will have dementia and that the prevalence of other neurodegenerative brain diseases, such as Alzheimer’s, will also increase. Alzheimer’s disease is one of the most common forms of dementia. There is no cure for the disease and eventually leads to death. Alzheimer’s is commonly diagnosed in people over the age of 65 years, although less-prevalent, Alzheimer’s can also occur much earlier. The pressure to produce successful treatments is rising but has proved unsuccessful so far. Scientists are increasingly looking at food products that can help slow disease progression and treat symptoms. The growing trends in nutraceutical usage are due to the belief that these compounds can postpone the development of various forms of dementia such as Alzheimer’s disease.
Cardiovascular disease is a term which is used for disorders of the heart and blood vessels and includes coronary heart disease. It is believed that low intake of fruits and vegetables is associated with high mortality in the case of cardiovascular diseases. Nutraceuticals in the form of vitamins, minerals, dietary fibers, antioxidants, and omega-3 polyunsaturated fatty acids together with physical exercise are recommended for prevention and treatment of this disease.
Cancer has emerged as a significant public health problem in developing countries. A healthy lifestyle and diet can help in the prevention of cancer. Carotenoids are a group of phytochemicals responsible for different colors of the foods. They have antioxidant activities and prove to be useful in cancer prevention. Recent interest in carotenoids has focused on the role of lycopene in human health, especially in cancer disease.
Endocrine health & diabetes
The WHO estimates that 347 million people worldwide have diabetes. Sustained exposure to high blood glucose is linked to the consumption of high fat and high sugar content foods. Functional food products, which release sugars slowly enable better glucose control, which can reduce the impact of diabetes for sufferers, and can also help to prevent the onset of type 2 diabetes.